University of South Carolina

Scholar Commons
Faculty Publications

Chemistry and Biochemistry, Department of

7-6-2012

IL-6 Regulation on Skeletal Muscle Mitochondrial Remodeling
During Cancer Cachexia in the ApcMin/+ Mouse
James P. White
University of South Carolina - Columbia

Melissa J. Puppa
University of South Carolina - Columbia

Shuichi Sato
University of South Carolina - Columbia

Song Gao
University of South Carolina - Columbia

Robert L. Price
University of South Carolina - Columbia, bob.price@uscmed.sc.edu

See next page for additional authors

Follow this and additional works at: https://scholarcommons.sc.edu/chem_facpub
Part of the Chemistry Commons

Publication Info
Published in Skeletal Muscle, Volume 2, 2012, pages 14-.
© Skeletal Muscle, 2012, Springer.

This Article is brought to you by the Chemistry and Biochemistry, Department of at Scholar Commons. It has been
accepted for inclusion in Faculty Publications by an authorized administrator of Scholar Commons. For more
information, please contact digres@mailbox.sc.edu.

Author(s)
James P. White, Melissa J. Puppa, Shuichi Sato, Song Gao, Robert L. Price, John W. Baynes, Matthew C.
Kostek, Lydia E. Matesic, and James A. Carson

This article is available at Scholar Commons: https://scholarcommons.sc.edu/chem_facpub/173

White et al. Skeletal Muscle 2012, 2:14
http://www.skeletalmusclejournal.com/content/2/1/14

Skeletal Muscle

RESEARCH

Open Access

IL-6 regulation on skeletal muscle mitochondrial
remodeling during cancer cachexia in the ApcMin/+
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Abstract
Background: Muscle protein turnover regulation during cancer cachexia is being rapidly defined, and skeletal
muscle mitochondria function appears coupled to processes regulating muscle wasting. Skeletal muscle oxidative
capacity and the expression of proteins regulating mitochondrial biogenesis and dynamics are disrupted in severely
cachectic ApcMin/+ mice. It has not been determined if these changes occur at the onset of cachexia and are
necessary for the progression of muscle wasting. Exercise and anti-cytokine therapies have proven effective in
preventing cachexia development in tumor bearing mice, while their effect on mitochondrial content, biogenesis
and dynamics is not well understood. The purposes of this study were to 1) determine IL-6 regulation on
mitochondrial remodeling/dysfunction during the progression of cancer cachexia and 2) to determine if exercise
training can attenuate mitochondrial dysfunction and the induction of proteolytic pathways during IL-6 induced
cancer cachexia.
Methods: ApcMin/+ mice were examined during the progression of cachexia, after systemic interleukin (IL)-6r
antibody treatment, or after IL-6 over-expression with or without exercise. Direct effects of IL-6 on mitochondrial
remodeling were examined in cultured C2C12 myoblasts.
Results: Mitochondrial content was not reduced during the initial development of cachexia, while muscle PGC-1α
and fusion (Mfn1, Mfn2) protein expression was repressed. With progressive weight loss mitochondrial content
decreased, PGC-1α and fusion proteins were further suppressed, and fission protein (FIS1) was induced. IL-6
receptor antibody administration after the onset of cachexia improved mitochondrial content, PGC-1α, Mfn1/Mfn2
and FIS1 protein expression. IL-6 over-expression in pre-cachectic mice accelerated body weight loss and muscle
wasting, without reducing mitochondrial content, while PGC-1α and Mfn1/Mfn2 protein expression was suppressed
and FIS1 protein expression induced. Exercise normalized these IL-6 induced effects. C2C12 myotubes administered
IL-6 had increased FIS1 protein expression, increased oxidative stress, and reduced PGC-1α gene expression without
altered mitochondrial protein expression.
Conclusions: Altered expression of proteins regulating mitochondrial biogenesis and fusion are early events in the
initiation of cachexia regulated by IL-6, which precede the loss of muscle mitochondrial content. Furthermore, IL-6
induced mitochondrial remodeling and proteolysis can be rescued with moderate exercise training even in the
presence of high circulating IL-6 levels.
Keywords: FIS1, PGC-1α, Exercise, IL-6r, MFN1, Cachexia, Mitochondria, Muscle, Autophagy
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Background
Although the regulation of muscle protein turnover during cachexia is rapidly being defined and the importance
of protein degradation processes is clearly demonstrated,
questions remain related to the underlying physiological
drivers that initiate alterations in these processes
throughout the progression of cachexia. There is accumulating scientific support for differential mechanisms
contributing to muscle loss during transition from the
initiation of cachexia toward severe cachexia [1,2]. We
have recently described differential regulation of muscle
protein turnover between the initial stages of cachexia
and severe body weight loss in the ApcMin/+ mouse [1].
With wasting conditions, a reduction in aerobic capacity
is clearly associated with the degree of body weight and
muscle mass loss [3,4]. Emerging evidence also provides
for a role of muscle mitochondria in the regulation of
muscle protein turnover [5]. Mitochondrial dynamics
and biogenesis are sensitive to contractile activity, in
particular endurance based exercise [6,7]; however, the
underlying mechanisms governing these processes during conditions of skeletal muscle wasting remain poorly
defined.
The coordinated balance between mitochondrial fission and fusion, referred to as mitochondria dynamics
[8], and muscle protein degradation have been described
by Romanello and Sandri [5]. The proposed model suggests mitochondrial dysfunction results in reactive oxidative species, susceptibility to apoptosis and energy
stress. These processes can lead to downstream activation of muscle proteolytic activation through AMPK and
FoxO activation [5]. Previous reports from our laboratory have shown cachectic ApcMin/+ mice to have
reduced muscle mitochondrial content associated with
increased apoptosis, suppression of the peroxisome
proliferator-activated receptor-gamma co-activator 1
alpha (PGC-1α) and altered regulation of mitochondrial
fission and fusion independent of oxidative stress [9,10].
In addition, we have recently shown increased activation
of AMPK and FoxO in muscle from severely cachectic
ApcMin/+ mice [1]. The increase in fission and decrease
in PGC-1α and mitochondrial fusion during cachexia
has been previously reported [9]; however, it is not
known if these alterations are early events in the onset
of muscle wasting, and have a regulatory role in the progression of cachexia.
Inflammatory cytokines are well-established mediators
of muscle wasting during cancer cachexia [11,12], and
anti-cytokine treatments can attenuate cachexia progression [1,13,14]. In the ApcMin/+ mouse model of cachexia,
the cytokine IL-6 is necessary for muscle wasting [15],
and over-expression of circulating IL-6 in precachectic
ApcMin/+ mice accelerates the development of cachexia
[16]. We have recently reported that IL-6 receptor (IL-
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6r) antibody administration to cachectic ApcMin/+ mice
attenuates further progression of cachexia [1], and was
associated with suppressed muscle protein degradation.
IL-6r antibody administration also represses lysosomal
and autophagy-related protein expression in cachectic
muscle [1,14]. There is supporting evidence for direct
effects of IL-6 on muscle mitochondrial dynamics as
treating cultured human myoblasts with IL-6 results in a
reduction in the mitochondrial fusion protein Mfn2 [17].
However, IL-6 regulation of muscle mitochondrial remodeling during the progression of cachexia is not clear
and warrants further attention.
Endurance exercise training increases skeletal muscle
oxidative capacity [6,7] and has been effectively used as
a counter measure for numerous muscle wasting conditions, including diabetes [18], chronic obstructive pulmonary disease (COPD) [19], renal disease [20] and
cardiac cachexia [21]. We have recently found that IL-6
over-expression-induced bodyweight and muscle mass
loss in ApcMin/+ mice is prevented by moderate treadmill
exercise, and is associated with an induction of muscle
oxidative protein expression [22]. Due to these findings,
the current study has pursued an enhanced understanding of how mitochondrial content, biogenesis and dynamics are regulated during the progression of cachexia
by IL-6. The purposes of this study were to 1) determine
IL-6 regulation on mitochondrial remodeling/dysfunction and the subsequent induction of muscle proteolysis
observed during the progression of cancer cachexia and
2) to determine if exercise training can attenuate mitochondrial dysfunction and the induction of proteolytic
pathways during IL-6 induced cancer cachexia. We
hypothesized the altered expression of muscle proteins
regulating mitochondria biogenesis, fission and fusion
would be regulated by IL-6 in muscle at the onset of
cachexia and precede mitochondrial content loss, which
is most prominent during late stage cachexia. We also
hypothesized that exercise training would suppress IL-6induced changes in mitochondria biogenesis, fission and
fusion and, in turn, inhibit the induction of muscle proteolytic activation and muscle wasting.

Methods
Animals

ApcMin/+ mice on a C57Bl/6 background were originally
purchased from Jackson Laboratories (Bar Harbor, ME,
USA) and bred at the University of South Carolina’s animal resource facility as previously described [23]. ApcMin/+
(n = 21) mice were group housed and were sacrificed at
various time points to provide stratification of body
weight loss to study regulation of muscle mitochondrial
remodeling during the progression of cachexia. The
groups were as follows; weight stable (WS), <5% (initial),
9 to 16% (intermediate) and >20% (severe) cachexia. To
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block the progression of cachexia, a subset of ApcMin/+
mice were treated with an IL-6 receptor antibody (n = 5)
or phosphate-buffered saline (PBS) control (n = 7) at
16 weeks after the onset of cachexia (See procedure
below). Wild-type controls were also treated with the IL-6
receptor antibody (n = 6) or PBS control (n = 6) at
16 weeks. To increase circulating IL-6 levels, wild-type
and ApcMin/+ mice (Control; n = 5 and + IL-6; n = 6) were
used for IL-6 over-expression experiments (See procedure
below). A subset of wild-type and ApcMin/+ mice were
exercised (See exercise methods) or served as cage controls. The room was maintained on a 12:12 light:dark cycle
with the light period starting at 0700. Mice were provided
standard rodent chow (Harlan Teklad Rodent Diet, #8604,
Madison, WI, USA) and water ad libitum. Body weight
and food intake were measured weekly. All animal experimentation was approved by the University of South Carolina’s Institutional Animal Care and Use Committee.
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two weeks after electroporation to determine plasma IL6 concentrations.
Treadmill protocol

At five weeks of age, mice were grouped into either exercise (n = 16) or cage control (n = 20) at which time they
started their training as previously described [22].
Briefly, acclimation consisted of running at a 5% grade
for a total of 20 minutes with gradual increase in speed
starting at 10 m/minute and increasing to 18 m/minute.
After the three days of acclimation mice, started on a
training regimen that consisted of a 5-minute warm up
at 10 m/minute at 5% grade followed by 55 minutes of
running at 18 m/minute at 5% grade. Mice were encouraged to run by gentle taps. Mice ran six days a week and
were given one day of recovery. After electroporation at
12 weeks, the mice received a two-day break from exercise before starting again. Mice ran until 14 weeks of age
when they were sacrificed.

IL-6 receptor antibody administration

The MR16-1 IL-6 receptor antibody was a generous gift
from Chugai Pharmaceutical Co., LTD, Tokyo, Japan. A
total of 300 μg/mouse of IL-6 receptor antibody was
administered by an intraperitoneal injection every 3 days
for 2 weeks starting at 16 weeks of age. PBS was injected
as a control vehicle.

Tissue collection

IL-6 over-expression

mtDNA PCR

In vivo intramuscular electroporation of an IL-6 plasmid
was used to increase circulating IL-6 levels in mice as
previously described [17,24]. The quadricep muscle was
used as a vessel to produce IL-6 and secrete it into circulation, and was not used for any analyses in this study.
The gastrocnemius muscle used in the study was not
subjected to electroporation. Briefly, mice were injected
with 50 μg of the IL-6 plasmid driven by the CMV promoter, or empty control vector, into the quadriceps
muscle. Mice were anesthetized with a 2% mixture of
isoflurane and oxygen (1 L/minute). The leg was shaved,
and a small incision was made over the quadricep
muscle. Fat was dissected away from the muscle, and the
plasmids were injected in a 50-μl volume of PBS. A
series of eight 50 ms, 100 V pulses was used to promote
uptake of the plasmid into myofibers, and then the incision was closed with a wound clip. Both vector control
and + IL-6 groups received the appropriate plasmid starting at 12 weeks of age. Mice were killed after two weeks
of IL-6 over expression.

Mitochondrial capacity was performed as previously
described [9]. DNA was isolated using DNAzolW Reagent
(Invitrogen, Carlsbad, CA, USA). Briefly, muscle (20 to
30 mg) was homogenized in 1 ml DNAzol, pelleted with
100% ethanol, and re-suspended in 8 mM NaOH. Quantitative real-time PCR analysis was carried out in 25 μl reactions consisting of 2x SYBR green PCR buffer (AmpliTaq
Gold DNA Polymerase, Buffer, dNTP mix, AmpErase
UNG, MgCl2) (Applied Biosystems, Foster City, CA,
USA), 0.150 μg DNA, DI water, and 60 nM of each primer. PCR was run with the DNA sample with Cytochrome B Forward, 5′ - ATT CCT TCA TGT CGG ACG
AG −3′; Cytochrome B Reverse, 5′ - ACT GAG AAG
CCC CCT CAA AT - 3′, Gapdh Forward, 5′ - TTG GGT
TGT ACA TCC AAG CA - 3′; Gapdh Reverse, 5′ - CAA
GAA ACA GGG GAG CTG AG - 3′. Samples were analyzed on an ABI 7300 Sequence Detection System. Reactions were incubated for 2 minutes at 50°C and 10
minutes at 95°C, followed by 40 cycles consisting of a 15-s
denaturing step at 95°C and 1-minute annealing/extending step at 60°C. Data were analyzed by ABI software (Applied Biosystems, Foster City, CA, USA). using the cycle
threshold (CT), which is the cycle number at which the
fluorescence emission is midway between detection and
saturation of the reaction. The 2-ΔΔ CT method [25] was
used to determine changes in gene expression between

Plasma IL-6

Plasma IL-6 levels were measured with a mouse-specific
ELISA (Biosource, Carlsbad, CA, USA) as previously
described [17]. Blood samples were taken under brief
isoflurane anesthesia from the retro-orbital eye sinus

Mice were given a subcutaneous injection of ketamine/
xylazine/acepromazine cocktail (1.4 ml/kg BW) before
the gastrocnemius was dissected. The gastrocnemius
muscles were rinsed in PBS, weighed, snap frozen in liquid nitrogen, and stored at −80°C until further analysis.
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Cytochrome B with Gapdh CT as the correction factor.
The ratio between mtDNA and nuclear DNA genes was
normalized to weight stable ApcMin/+ mice and wild-type
PBS treated mice and used as an index of mitochondrial
content. This method has been modified from a previously
used technique to determine mitochondrial content in
muscle [26].

MA, USA) were incubated with the membranes at
1:2,000 dilutions for 1 h in 5% milk in TBS-T. Enhanced
chemiluminescence (ECL) (GE Healthcare Life Sciences,
Piscataway, NJ, USA) was used to visualize the antibodyantigen interactions. Images were digitally scanned and
blots were quantified by densitometry using scientific
imaging software (Scion Image, Frederick, MD, USA).

C2C12 cell culture

RNA isolation, cDNA synthesis, and real time PCR

C2C12 myoblasts purchased from American Type Culture Collection (Manassas, VA, USA) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% FBS, 50 U/ml penicillin and 50 μg/ml
streptomycin (Fisher Scientific, Pittsburg, PA, USA).
Upon reaching confluence, myoblast differentiation was
induced for 72 h in DMEM supplemented with 2% heatinactivated horse serum (HIHS), 50U/ml penicillin and
50 μg/ml streptomycin. After 72 h differentiation, IL-6
(Sigma, St. Louis, MO, USA) was added to serum-free
DMEM and incubated for 24 h. Cells were harvested by
washing with ice-cold PBS and then scraped in ice-cold
lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA,
1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate,
5 mM NaF, 1 mM β-glycerolphosphate, 1 mM NaVO3
and 1/200 protease inhibitor cocktail (Sigma, P8340), pH
8.0). After sonication, cell debris was removed by centrifugation, and the supernatant was stored at −80°C. Protein concentrations were measured by the Bradford
assay (Bio-Rad, Hercules, CA, USA) and the samples
were used for Western blot analysis. All cell culture
experiments were run in triplicates and all experiments
were replicated.

RNA isolation, cDNA synthesis and real-time PCR were
performed as previously described [28], using reagents
from Applied Biosystems (Foster City, CA, USA). Fluorescence labeled probes for C2 proteasomal subunt, C7
proteasomal subunit, atrogin-1, Bax (FAM dye) and the
ribosomal RNA 18 s (VIC dye) were purchased from
Applied Biosystems and quantified with TaqMan Universal mastermix (Applied Biosystems, Foster City, CA,
USA) PGC-1 (forward- 5′ AAGACGGATTGCCCTCATTT 3′, reverse 5′ AGTGCTAAGACCGCTGCATT
3′) and GAPDH primers were purchased from IDT
(Coralville, Iowa, USA) and run using SYBR green PCR
buffer. Data were analyzed by ABI software using the
cycle threshold (CT), which is the cycle number at which
the fluorescence emission is midway between detection
and saturation of the reaction.

Western blotting

Statistical analysis

Western blot analysis was performed as previously
described [24]. Briefly, frozen gastrocnemius muscle was
homogenized in Mueller buffer and protein concentration determined by the Bradford method [27]. Crude
muscle homogenate 40 μg was fractionated on 8% to
10% SDS-polyacrylamide gels. Gels were transferred to
PVDF membranes overnight. Membranes were Ponceau
stained to verify equal loading of each gel. Membranes
were blocked overnight in 5% milk in Tris-buffered saline with 0.1% Tween-20 (TBS-T). Primary antibodies
for CoxIV, Cytochrome C, Atg5, Beclin-1, LC3β,
GAPDH and FoxO (Cell Signaling, Danvers, MA, USA),
Mfn1, Mfn2 (Novus Biologicals, Littleton, CO, USA),
Fis1 (Sigma), PGC-1α (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), p-FoxO (Millipore, Billerica, MA,
USA) and 4-hydroxynonenal (alpha diagnostics) were
diluted 1:1,000 to 1:500 in 5% milk in TBS-T followed by
1 h incubation with membranes at room temperature.
Anti-rabbit or mouse IgG horseradish-peroxidase conjugated secondary antibodies (Cell Signaling, Danvers,

A one-way ANOVA was used to determine differences
between ApcMin/+ mice separated by percentage body
weight loss and all cell culture experiments. A two-way
ANOVA was used to determine differences among variables in the IL-6 receptor antibody and exercise experiments. Post-hoc analyses were performed with Student
Newman-Keuls methods. Significance was set at P
<0.05.

Transmission electron microscopy

Samples of red quadriceps muscle were fixed in 2.5%
glutaraldehyde and prepared as previously described
[29]. Mitochondrial size was determined by tracing the
outline of mitochondria at 15,000X magnification using
Image J software (NIH, Bethesda, MA, USA).

Results
Mitochondrial loss during severe cachexia is associated
with a reduction in biogenesis and alterations in fission/
fusion dynamics. ApcMin/+ mice were sacrificed between
14 and 20 weeks of age and then categorized as having
no weight loss (weight stable), ≤5% body weight loss
(initial), 6 to 19% weight loss (intermediate) and >20%
loss (severe). While muscle mitochondria content was
not different between weight stable mice and those exhibiting initial body weight loss, there was a 45% reduction
(P = 0.03, Figure 1A) during intermediate body weight
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loss and a further reduction (63%; P = 0.005) with severe
weight loss. Mitochondrial protein expression mirrored
mitochondria content, with cytochrome C and Cox IV
protein expression being reduced by 43% (P = 0.002;
Figure 1C) and 21% (P = 0.002; Figure 1D) with intermediate weight loss and having expression of both proteins further reduced with severe weight loss. PGC-1α, a
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marker of mitochondrial biogenesis was reduced 53%
(P = 0.003; Figure 1E) during intermediate stage cachexia
and reduced further with the progression to severe body
with loss (P = 0.002). The changes in mitochondrial protein expression and protein expression related to fission/
fusion are associated with altered mitochondrial morphology in skeletal muscle. Electron microscopy images of

Figure 1 Mitochondrial content, biogenesis and morphology are altered during the progression of cachexia. ApcMin/+ mice were
grouped by percentage of body weight loss to study muscle oxidative capacity during the progression of cachexia. A) Mitochondrial content as
determined by the mitochondrial:nuclear DNA ratio. B) Representative Western blot of cytochrome C, CoxIV and PGC-1α protein expression
throughout the progression of cachexia. C) Cytochrome C, D) CoxIV and E) PGC-1α protein expression normalized to weight stable mice.
Representative EM images of intramuscular mitochondria in F) wild-type, G) ApcMin/+ mice with mild cachexia and H) ApcMin/+ mice with severe
cachexia. I) Mitochondrial size and J) mitochondrial size distribution. Values are means ± SE. Significance was set at P <0.05. † Signifies different
from weight stable groups. $ Signifies difference from mice with 6 to 19% body weight loss. WS, weight stable.
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skeletal muscle from wild-type (Figure 1F), weight stable
ApcMin/+ mice (Figure 1G) and severely cachectic ApcMin/+
mice (Figure 1H). Mitochondrial size was reduced in
weight stable ApcMin/+ mice compared to wild-type mice
(Figure 1I). Mitochondrial size in cachectic ApcMin/+ mice
was highly variable; however, when plotted as percentage
mitochondrial size distribution there was a shift towards
smaller mitochondria (Figure 1J) in cachectic ApcMin/+
mice when compared to weight stable ApcMin/+ mice and
wild-type mice.
Mitochondrial fission/fusion proteins are differentially
expressed during the progression of cachexia. Contrasting with muscle mitochondria content, the expression of
mitofusin 1 (Mfn1) and Mfn2 proteins were reduced 22
and 31% (P = 0.04; Figure 2B, C) with the initiation of
weight loss. With the progression of weight loss, muscle
MFN1 and MFN2 expression was further reduced. There
was no change in mitochondrial fission protein (FIS1)
expression between weight stable mice and those having
initial body weight loss, but FIS1 expression was strongly
induced 2.5-fold (P = 0.002; Figure 2D) with the progression of body weight loss. Pro-apoptotic Bax mRNA
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expression was increased in ApcMin/+ mice with intermediate and severe body weight loss when compared to
weight stable ApcMin/+ mice while no differences were
detected in ApcMin/+ mice showing initial body weight
loss (Figure 2E).
IL-6 inhibition attenuated mitochondrial loss in ApcMin/+
mice that have initiated body weight loss. We have previously reported inhibition of IL-6 signaling can attenuate
the progression of cachexia and subsequent loss of muscle
mass [1]. Here we show that the preservation of muscle
mass is associated with the maintenance of mitochondrial
biogenesis and dynamics. Control ApcMin/+ mice treated
with PBS had a 59% reduction in mitochondrial content
(P = 0.01; Figure 3A) and a reduction in cytochrome C and
Cox IV and protein expression (P = 0.003; Figure 3C, D)
when compared to wild-type controls, respectively. Inhibition of systemic IL-6 signaling by an IL-6 receptor antibody for two weeks attenuated the loss of mitochondrial
content and repressed expression of mitochondrial proteins (Figure 3A, C, D). However, mitochondrial content
and protein expression remained reduced compared to
wild-type controls. Furthermore, IL-6 receptor antibody

Figure 2 Mitochondrial dynamics are altered during the progression of cachexia. A) Representative Western blot of Mfn1, Mfn2 and FIS1
protein expression during the progression of cachexia. B) Mfn1, C) Mfn2 and D) FIS1 protein expression normalized to weight stable mice. E) Bax
mRNA expression normalized to weight stable mice. Values are means ± SE. Significance was set at P <0.05. † Signifies the difference from WS
groups. & Signifies the difference from mice with ≤5% body weight loss. $ Signifies the difference from mice with 6 to 19% body weight loss.
WS, weight stable.
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Figure 3 IL-6 inhibition attenuates the loss in mitochondrial content and biogenesis in the ApcMin/+ mouse. Wild-type and ApcMin/+ mice
were treated with an IL-6 receptor antibody for two weeks to inhibit IL-6 signaling. A) Mitochondrial content as determined by the mitochondrial:
nuclear DNA ratio. B) Representative Western blot of Cytochrome C, Cox IV and PGC-1α protein in wild-type and ApcMin/+ mice treated with an
IL-6 receptor antibody or PBS control. C) Cytochrome C, D) CoxIV and E) PGC-1α protein expression normalized to wild-type PBS control mice.
Values are means ± SE. Significance was set at P <0.05. *Signifies the difference within treatment. † Signifies the difference within genotype.

treatment attenuated the reduction in PGC-1α protein expression (P = 0.002; Figure 3E).
IL-6 inhibition attenuates the loss of mitochondrial fusion and prevents the expression of fission protein expression. Mfn2 protein expression was reduced 39% (P<0.001;
Figure 4B) in PBS treated ApcMin/+ mice when compared
to wild-type controls. IL-6 receptor antibody treatment
increased Mfn2 expression in ApcMin/+ mice (Figure 4B),
but not to wild-type levels. FIS1 protein expression was

induced 2-fold (P <0.001; Figure 4C) in PBS treated
ApcMin/+ mice and this induction was prevented by IL-6r
antibody administration. The IL-6r receptor antibody did
not alter muscle Mfn2 or FIS1 expression in wild-type mice.
Bax mRNA expression was increased two-fold in PBS treated ApcMin/+ mice (Figure 4D) which was reduced 33%
(P = 0.02) with IL-6 receptor antibody treatment.
IL-6-induced muscle wasting and associated alterations in mitochondrial dynamics are rescued with
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Figure 4 IL-6 inhibition restores mitochondrial dynamics and
reduces apoptosis in the ApcMin/+ mouse. A) Representative
Western blot of Mfn2 and FIS1 protein expression in wild-type and
ApcMin/+ mice treated with an IL-6 receptor antibody or PBS control.
B) Mfn2 and C) FIS1 protein expression normalized to PBS treated
wild-type mice. D) Bax mRNA expression normalized to PBS treated
wild-type mice. Values are means ± SE. Significance was set at P <
0.05. * Signifies the difference within treatment. † Signifies the
difference within genotype.

exercise training. Two weeks of IL-6 over-expression
reduced gastrocnemius muscle mass by 12%, which was
prevented when mice were exercise training during IL-6
over-expression (Figure 5A). Systemic IL-6 overexpression was not sufficient to alter mitochondrial protein expression in the gastrocnemius of ApcMin/+ mice
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initiating cachexia (Figure 5C, D). However, IL-6 overexpression decreased PGC-1α protein expression 56%
(Figure 5E) in ApcMin/+ mice. In contrast, IL-6 overexpression did not decrease PGC-1α protein expression
in exercise trained ApcMin/+ mice. Lastly, IL-6 overexpression or exercise training did not affect muscle oxidative damage as represented by quantification of 4hydroxynonenal (4HNE)-modified proteins (Figure 5F).
Exercise training improves IL-6 induced alterations in
mitochondrial dynamic and apoptosis. Exercise is a potent method to increase oxidative capacity in skeletal
muscle [7], and we have recently shown exercise can
counteract muscle loss during IL-6-induced cachexia
[22]. IL-6 over-expression decreased mitochondrial fusion proteins Mfn1 and Mfn2 57% and 42%, respectively
(Figure 6B, C). Exercise was able to increase fusion protein expression by roughly two-fold despite IL-6 overexpression. Mitochondrial fission protein FIS1 was
increased 81% with IL-6 over-expression which was prevented by exercise (Figure 6D). Phosphorylation of
FoxO, a potent regulator of muscle proteolysis was
decreased 44% (P = 0.003; Figure 6E) indicating increased
transcriptional activation with IL-6 over-expression. Exercise training prevented the reduction in FoxO phosphorylation independent of circulation IL-6 levels. Bax
mRNA expression was increased roughly two-fold
(Figure 6F) with IL-6 over-expression which was also
prevented by exercise training.
IL-6 over-expression in ApcMin/+ mice increased
muscle proteolysis through both ubiquitin dependent
and autophagy related pathways. Autophagy related protein expression was increased with IL-6 over-expression
as Atg5, Beclin-1 and LC3β were increased by 76%, 74%
and 62% (P <0.05; Figure 7B, C, D) respectively. Exercise
training prevented the induction of Atg5 and Beclin-1
and attenuated the induction of LC3β by 28%
(P = 0.008). IL-6 over-expression induced gene expression related to the ubiquitin proteasomal pathway as
well. The muscle specific E3 ligase, Atrogin-1 mRNA expression was induced by two-fold (Figure 7E) while
mRNA expression of proteasomal subunits C2 (Figure 7F)
and C7 (Figure 7G) were increased roughly two-fold. Exercise training attenuated gene expression related to ubiquitin dependent proteolysis.
IL-6 treatment to C2C12 myotubes induces Fis1 and
oxidative damage independent of changes in PGC-1α
and mitochondrial proteins. C2C12 myotubes were treated with 0 ng/ml IL-6 (Control), 20 ng/ml (low) and
100 ng/ml (high). A total of 100 ng/ml of IL-6 induced
Fis1 protein expression 64% (P = 0.02; Figure 8B) when
compared to control while no change in Fis1 expression
was detected in the low dose of IL-6. The low dose of
IL-6 trended (P = 0.07) to decrease PGC-1α mRNA expression while the high IL-6 dose decreased PGC-1α
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Figure 5 (See legend on next page.)
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(See figure on previous page.)
Figure 5 IL-6 over-expression induced muscle wasting and reduced PGC-1α which are rescued with exercise training. ApcMin/+ mice
underwent 12 weeks of moderate exercise training or served as sedentary cage controls and over-expressed circulating IL-6 or received a control
vector. A) Gastrocnemius muscle mass. B) Representative Western blot of cytochrome C, CoxIV and PGC-1α protein in the gastrocnemius of
ApcMin/+ mice. C) Cytochrome C, D) CoxIV and E) PGC-1α protein expression normalized to sedentary mice treated with the control vector.
F) Upper - representative Western blot of 4-hydroxynonenal (4HNE)-modified proteins; lower - 4HNE-modified protein expression normalized to
sedentary control mice. Values are means ± SE. Significance was set at P <0.05. CC, cage control; ME, main effect;. Wt, wild-type. * Signifies the
difference from cage control vector mice.

mRNA expression by roughly 80% (P <0.001; Figure 8E)
without any changes in mitochondrial proteins cytochrome C (Figure 8C) and Cox IV (Figure 8D). 4HNE
modified proteins were increased 43% (P = 0.04; Figure 8F)
with the high dose of IL-6 when compared to control. The
low dose of IL-6 did not affect 4HNE modified proteins in
C2C12 myotubes.

Discussion
Skeletal muscle mitochondria have emerged as a critical
regulator of muscle protein turnover [5]. Both mitochondrial loss and altered fission/fusion regulation are
associated with muscle wasting [30-32]. Related to these
processes are induction of reactive oxygen species, apoptosis and activation of the ubiquitin and autophagy
dependent proteolysis [5]. We have previously shown a
reduction in muscle oxidative capacity and altered mitochondrial dynamics in both oxidative and glycolytic
muscle in severely cachectic ApcMin/+ mice [9]. In
addition, we have recently reported the induction of
both ubiquitin and autophagy related muscle protein
degradation during the progression of cachexia [1]. Here
we report the novel finding that the expression of proteins regulating mitochondrial biogenesis and mitochondrial dynamics are disrupted early in the development of
cachexia and precede a reduction in mitochondria content. Further, alterations in the expression of these proteins can be suppressed by the administration of an IL6r antibody after the initiation of cachexia. We also report that exercise training can improve the expression of
proteins regulating mitochondrial biogenesis and dynamics, which is associated with the attenuation of
muscle protein degradation even when systemic IL-6
levels are comparable to what is typically observed during severe cachexia. Lastly, we show IL-6 treatment to
C2C12 myotubes induced FIS1 expression and oxidative
damage without changes in oxidative protein expression.
While we previously reported a reduction in mitochondrial content and protein expression in severely
cachectic ApcMin/+ mice [9], that study was not able to
examine changes during the progression of the disease.
Our current study expanded on these prior findings by
stratifying ApcMin/+ mice into groups of incremental
weight loss. We report that the loss of muscle mitochondria is not necessary for the significant amount of

muscle mass loss (approximately 20%) that occurs at the
onset of cachexia. However, there was an incremental
loss of skeletal muscle mitochondria with further progression of cachexia, which coincides with the induction
of apoptosis in the muscle [10], and the induction of
proteins regulating autophagy [1]. We report the novel
finding that muscle mitochondrial morphology is altered
during the initiation and progression of cancer cachexia.
Late stage cachexia in ApcMin/+ mice is also associated
with a surge in circulating IL-6 and a reduction in volitional physical activity [12]. While our current study
reports that two weeks of elevated circulating IL-6 was
not sufficient to reduce muscle mitochondrial content,
the IL-6r antibody treatment after the initiation of cachexia was able to significantly attenuate the loss of mitochondria. Skeletal muscle mitochondrial content retains
plasticity related to the amount of contractile activity
being performed by the muscle [33]. Here we also show
that exercise training prior to and during overexpression of IL-6 in the ApcMin/+ mouse could not only
prevent the suppression of mitochondrial biogenesis, but
increase oxidative protein expression above control
values regardless of cachectic stimuli. Further work is
needed to understand the association between sedentary
behavior and chronically high IL-6 levels, which are
characteristics of late stage cachexia, on the processes
regulating mitochondria loss during the progression of
cachexia.
The suppression of mitochondria biogenesis during the
initiation of cachexia could be a critical early event that
leads to mitochondrial dysfunction and loss in later stages
of the disease. Interestingly, the reduction in mTOR signaling, and specifically the mTORC1 complex, in cachectic muscle may impact mitochondrial content through the
repressed transcription of genes involved in oxidative metabolism. The mTORC1 complex can act with PGC-1α to
activate transcription of oxidative genes [34], and muscle
mitochondria content is severely reduced in mice with a
muscle specific RAPTOR knockout, which disrupts the
formation of the mTORC1 complex [35]. We have
reported the phosphorylation of RAPTOR, which
decreases mTORC1 activation, is increased during the
progression of cachexia in the ApcMin/+ mouse [1]. PGC1α has a well-documented role in the regulation of skeletal
muscle oxidative capacity [36,37] and, recently, it has been
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Figure 6 Exercise training reduces IL-6 induced alterations in mitochondria dynamics, apoptosis and FoxO phosphorylation.
A) Representative Western blot of Mfn1, Mfn2 and FIS1 protein in the gastrocnemius of ApcMin/+ mice. B) Mfn1, C) Mfn2 and D) FIS1 protein
expression normalized to sedentary mice treated with the control vector. E) upper - Representative Western blot of total and phosphorylated
FoxO proteins; lower - ratio of phosphorylated to total FoxO protein expression normalized to cage control mice. F) Bax mRNA expression. Data
are normalized to cage control mice. Values are means ± SE. Significance was set at P <0.05. CC, cage control; ME, main effect; Wt, wild-type.
*Signifies the difference from cage control vector mice.

shown to be involved with numerous cellular processes including protein degradation [38], mTOR activity [34],
apoptosis [39] and regulation of ROS [40]. A reduction in
PGC-1α expression has been previously shown in several
wasting diseases [41-45], including cachexia [9]. The reduction in muscle PGC-1α expression coincided with circulating IL-6 levels, being repressed by IL-6 over-

expression before a reduction in oxidative capacity, and
being further reduced with the progression of cachexia.
Additionally, the administration of the IL-6r antibody attenuated the loss in PGC-1α expression and exercise served
to induce PGC-1α expression in muscle that demonstrated an attenuated catabolic response related to muscle
wasting. Furthermore, we report IL-6 can have a direct
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Figure 7 Autophagy and ubiquitin dependent proteolysis are induced with IL-6 over-expression and attenuated with exercise training.
A) Representative Western blot of Atg5, Beclin1 and LC3β protein in the gastrocnemius of ApcMin/+ mice. B) Atg5, C) Beclin1 and D) LC3β protein
expression normalized to sedentary cage control mice. E) Atrogin1 mRNA. F) C2 and G) C7 proteasomal subunit mRNA. Data are normalized to
cage control groups for wild-type and ApcMin/+ mice. Values are means ± SE. Significance was set at P <0.05. *Signifies the difference from cage
control vector mice. † Signifies the difference within IL-6 treatment.

effect on mitochondria biogenesis as C2C12 myotubes
treated with IL-6 resulted in a reduction in PGC-1α
mRNA expression. Therefore, induction of mitochondrial
biogenesis during the initiation of cachexia may be an excellent target for therapeutic intervention during the initiation of cachexia.
The coordination of mitochondrial fission and fusion,
referred to as mitochondrial dynamics, have been recently identified as critical components of mitochondrial
function, morphology and distribution [6,46]. Fusion
proteins Mfn1 and Mfn2 can promote mitochondrial
elongation and activity, and regulate mitochondrial

membrane potential and glucose oxidation in cultured
cells [47]. We report that the expression of both Mfn1
and Mfn2 proteins are repressed during pre-cachexia,
and this is one of the earliest alterations in protein expression related to oxidative metabolism we have found
in skeletal muscle. There is a further reduction in Mfn1
and Mfn2 protein expression as cachexia progresses.
Mitochondrial fusion protein expression appears to be
IL-6 sensitive. It has been previously shown that IL-6
treatment to muscle cells reduced mitochondrial fusion
protein Mfn2 gene expression [17]. In the current report, IL-6 over- expression repressed expression and IL-
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Figure 8 IL-6 treatment on C2C12 myotubes induces FIS1 expression and a reduction in PGC-1α mRNA. A) Representative Western blot of
FIS1, Cytochrome C and CoxIV protein in C2C12 myotubes treated with 0, 20 and 100 ng/ml of IL-6. B) FIS1, C) Cytochrome C and D) CoxIV C
protein expression and PGC-1α mRNA E) expression normalized to C2C12 myoblasts treated with vehicle control (0 ng/ml IL-6). Values are
means ± SE. Significance was set at P <0.05. *Signifies the difference from 0 ng/ml control.
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6r antibody administration increased expression of
Mfn2. Interestingly, exercise was able to increase both
Mfn1 and Mfn2 expression regardless of IL-6 levels.
PGC-1α and PGC-1β can regulate Mfn2 gene expression
in conjunction with the estrogen-related receptor-α
[3,48]. A reduction in Mfn2 has been observed in muscle
from type 2 diabetic [17,49] and obese patients [17].
However, patients with chronic heart failure and weight
loss did not show a change in muscle Mfn2 indicating
the role of Mfn2 in muscle wasting may be different depending on disease type and severity [50].
Related to the regulation of mitochondrial fission, our
data show an increase in muscle FIS1 protein expression
in the later stages of cachexia, which could also be
induced by systemic over-expression of IL-6. Furthermore, we are the first to show that FIS1 gene expression
in C2C12 myotubes is increased when treated with IL-6.
The role of FIS1 during wasting diseases is currently unknown, but FIS1 over-expression is pro- apoptotic in
skeletal muscle [51-53] and is associated with the production of reactive oxygen species [5] and activation of
muscle protein degradation [32]. Muscle apoptosis is
commonly observed during cancer cachexia [10,54,55].
We have previously shown the induction of apoptosis in
muscle from severely cachectic ApcMin/+ mice while no
evidence of apoptosis was observed in moderately cachectic ApcMin/+ mice [10]. Here we show FIS1 was only
increased during later stages of cachexia, which coincided with the induction of pro-apoptotic Bax mRNA
expression, which further suggests an association between mitochondrial fission and apoptosis. Furthermore,
exercise training was able to reduce fission protein and
Bax mRNA expression. To determine whether the
exercise-induced suppression of fission and apoptosis
coincided with inhibition in muscle degradation, we
measured markers of autophagy and ubiquitin dependent
proteolysis. We report exercise was able to attenuate activation of FoxO and pathways related to both autophagy
and the ubiquitin proteasomal system. This effect was
similar to what was observed by Romanello et al. when
they showed inhibition of mitochondrial fission prevented
muscle wasting induced by starvation or FoxO overexpression [32]. Together, these findings suggest improvements in mitochondrial dynamics could be a target for
exercise-induced protection from muscle protein degradation and eventual muscle wasting.
The production of reactive oxygen species is associated
with mitochondrial remodeling and activation of proteolytic pathways during muscle wasting [5]. The role of reactive oxygen species during muscle wasting in ApcMin/+
mice is still unclear. We previously reported no changes in
muscle oxidative damage during cachexia in the ApcMin/+
mouse [9] and currently show no changes in oxidative
damage with systemic IL-6 over-expression. However, IL-6
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treatment on C2C12 myotubes increased indices of reactive oxygen species. Further investigation is needed to determine the role of ROS production in regulating muscle
wasting during cachexia.

Conclusions
In summary, we show the reduction in mitochondrial content during the progression of cachexia in the ApcMin/+
mice occurs during later stages of body weight loss. The
loss of mitochondria is preceded by the reduction in
PGC-1α and mitochondrial fusion proteins Mfn1 and 2
during the initial stages of cachexia, while the induction of
fission protein FIS1 occurs with the progression of cachexia. In this study, we used an IL-6 receptor antibody to
inhibit IL-6 signaling after the initiation of cachexia, used
systemic IL-6 over-expression to initiate cachexia, and also
examined the effect of exercise to improve muscle mitochondrial function during IL-6 induced cachexia. Lastly,
C2C12 myoblasts were treated with IL-6 to determine direct effects of IL-6 on mitochondrial remodeling/function.
We have shown IL-6 inhibition and exercise training can
prevent the progression of cachexia in ApcMin/+ mice.
Here, we show both therapies can prevent the loss of
mitochondrial content by preserving PGC-1α and fusion
protein expression, while preventing the increase in fission
protein expression. These changes were associated with a
reduction in muscle wasting and pathways related to
muscle protein degradation. Our in vitro data extended
our finding by showing IL-6 can directly increase FIS1 expression in muscle cells. Further research needs to examine if therapies to maintain muscle oxidative capacity are
most effective when administered before significant body
weight loss develops. The findings of this study enhance
our understanding of the interactions between muscle oxidative capacity and the regulation of muscle mass during
cachexia, thus, providing further rationale to explore the
interconnection between oxidative capacity and its role in
regulating muscle mass during wasting diseases.
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